argenx to Present at Wedbush PacGrow Healthcare Conference

 

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York on Tuesday, August 15, 2017 at 1:20 p.m. EDT.

The presentation will be webcast live and may be accessed on the argenx website at www.argenx.com or by clicking here. A replay of the webcast will be available for 90 days following the presentation.

Note

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
www.argenx.com

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?